Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAP | Q12884 | 5/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.37 |
| ▸ | FURIN | P09958 | 2/20 | 0.35 |
| ▸ | MAP1LC3B | Q9GZQ8 | 2/20 | 0.35 |
| ▸ | NPY1R | P25929 | 2/20 | 0.34 |
| ▸ | NPY4R | P50391 | 2/20 | 0.34 |
| ▸ | GLP1R | P43220 | 3/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19026412 | 1.00 | FAP (0.39) | FAPOPRK1FURINMAP1LC3BNPY1R | |
| SCHEMBL21570028 | 1.00 | FAP (0.39) | FAPOPRK1FURINMAP1LC3BNPY1R | |
| SCHEMBL24898929 | 1.00 | FAP (0.39) | FAPOPRK1FURINMAP1LC3BNPY1R | |
| SCHEMBL30483105 | 1.00 | FAP (0.39) | FAPOPRK1FURINMAP1LC3BNPY1R | |
| SCHEMBL21570074 | 0.94 | FAP (0.39) | FAPOPRK1FURINMAP1LC3BNPY1R | |
| SCHEMBL24224636 | 0.94 | FAP (0.40) | FAPOPRK1FURINMAP1LC3BNPY1R | |
| SCHEMBL23943282 | 0.94 | FAP (0.40) | FAPOPRK1FURINMAP1LC3BNPY1R | |
| SCHEMBL22138625 | 0.94 | FAP (0.40) | FAPOPRK1FURINMAP1LC3BNPY1R | |
| SCHEMBL25450085 | 0.94 | FAP (0.40) | FAPOPRK1FURINMAP1LC3BNPY1R | |
| SCHEMBL16946352 | 0.94 | FAP (0.40) | FAPOPRK1FURINMAP1LC3BNPY1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230285581-A1 | RIFAMYCIN ANALOGS AND ANTIBODY-DRUG CONJUGATES THEREOF | REGENERON PHARMACEUTICALS, INC. (US) | 2023-09-14 | — | — | US | disclosed |
| US-11666658-B2 | Rifamycin analogs and antibody-drug conjugates thereof | Regeneran Pharmaceuticals, Inc. (US) | 2023-06-06 | — | — | US | disclosed |
| US-11377502-B2 | Anti-MSR1 antibodies and methods of use thereof | REGENERON PHARMACEUTICALS, INC. (US) | 2022-07-05 | — | — | US | disclosed |
| US-20200368361-A1 | RIFAMYCIN ANALOGS AND ANTIBODY-DRUG CONJUGATES THEREOF | REGENERON PHARMACEUTICALS, INC. (US) | 2020-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200368361-A1 | RIFAMYCIN ANALOGS AND ANTIBODY-DRUG CONJUGATES THEREOF | ASGR1, CUTA, SRPRA | FAP 4038/4885OPRK1 4045/4885FURIN 794/4885 |
| US-11666658-B2 | Rifamycin analogs and antibody-drug conjugates thereof | ASGR1, CUTA, SRPRA | FAP 4038/4885OPRK1 4045/4885FURIN 794/4885 |
| US-20230285581-A1 | RIFAMYCIN ANALOGS AND ANTIBODY-DRUG CONJUGATES THEREOF | ASGR1, CUTA, SRPRA | FAP 4038/4885OPRK1 4045/4885FURIN 794/4885 |
| US-11377502-B2 | Anti-MSR1 antibodies and methods of use thereof | CD47, MSR1, LDLR | FAP 4480/4885OPRK1 1746/4885FURIN 2044/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.